Resumen: Cancer heterogeneity constitutes the major source of disease progression and therapy failure. Tumors comprise functionally diverse subpopulations, with cancer stem cells (CSCs) as the source of this heterogeneity. Since these cells bear in vivo tumorigenicity and metastatic potential, survive chemotherapy and drive relapse, its elimination may be the only way to achieve long-term survival in patients. Thanks to the great advances in the field over the last few years, we know now that cellular metabolism and stemness are highly intertwined in normal development and cancer. Indeed, CSCs show distinct metabolic features as compared with their more differentiated progenies, though their dominant metabolic phenotype varies across tumor entities, patients and even subclones within a tumor. Following initial works focused on glucose metabolism, current studies have unveiled particularities of CSC metabolism in terms of redox state, lipid metabolism and use of alternative fuels, such as amino acids or ketone bodies. In this review, we describe the different metabolic phenotypes attributed to CSCs with special focus on metabolism-based therapeutic strategies tested in preclinical and clinical settings. Idioma: Inglés DOI: 10.3389/fphar.2019.00203 Año: 2019 Publicado en: Frontiers in Pharmacology 10, 203 (2019), [26 pp] ISSN: 1663-9812 Factor impacto JCR: 4.225 (2019) Categ. JCR: PHARMACOLOGY & PHARMACY rank: 52 / 270 = 0.193 (2019) - Q1 - T1 Factor impacto SCIMAGO: 1.228 - Pharmacology (medical) (Q1) - Pharmacology (Q1)